Barely Significant
← all excerpts

Osimertinib-chemotherapy synergy in <i>EGFR</i>-mutant NSCLC: advancing central nervous system control amidst toxicity considerations.

Transl Cancer Res · 2025 · PMC12079210 · PMID 40386260

Europe PMCDOI
1
hedged sentence
0.9300
closest p · 18.6× alpha
0.9300
boldest claim

The sentences

showed a trendP=0.93not close (p > 0.1)
In the measurable cohort, the CNS objective response rates showed a trend towards more complete responses, suggesting that the addition of chemotherapy may improve the depth of response over monotherapy (48% vs. 16%, P=0.93).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.